0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessWe did not find any significant unfavourable interaction between regorafenib and patients' co-medications, from any pharmacological class (e.g. anti-acid), either in terms of efficacy or regarding the occurrence of adverse events. These results are reassuring for the safety of regorafenib administered in association with co-medications.
F Rethouze, Severine Risbourg, Camille Schiffler, Sylvie Chabaud, Antoine De Courreges, Marie‐Cécile Le Deley, Jean Yves Blay, Frédéric Feutry, Marta Jimenez, Marie Vanseymortier, Nicolas Penel, Florence Duffaud, Loïc Lebellec (2025). COREGO: drug–drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials. , 10(6), DOI: https://doi.org/10.1016/j.esmoop.2025.105117.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2025
Authors
13
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1016/j.esmoop.2025.105117
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
